Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab
Related Experiment Videos
Kotoe Iesato1, Naoki Hatakeyama, Masaki Yamamoto
1Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan.
Abstract:
Some infants with acute immune thrombocytopenic purpura (ITP) do not respond to first-line therapy, and currently there is no consensus on therapy for these refractory cases. We describe a 12-week-old infant with acute ITP who was unresponsive to intravenous immunoglobulin and corticosteroid, and developed gastrointestinal bleeding. Several combination therapies were unsuccessful. After four doses of rituximab followed by intravenous immunoglobulin and corticosteroid, his platelet counts gradually increased. Combined therapy which includes rituximab may be a promising treatment for severe acute refractory ITP.
Related Concept Videos
Respiratory Syncytial Virus Disease
Rheumatic Heart Disease III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Venous Thrombosis III: Interprofessional Care